Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses

This publication has 21 references indexed in Scilit:

• Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system
  Vaccine, 1996
• Generation of Tumor Specific CTL Using Genetically Modified Antigen Presenting Cells
  Journal of Immunotherapy, 1995
• Induction of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Cytolytic T Lymphocyte Responses in Seronegative Adults by a Nonreplicating, Host-Range-Restricted Canarypox Vector (ALVAC) Carrying the HIV-1MN env Gene
  The Journal of Infectious Diseases, 1995
• Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species
  Vaccine, 1995
• Carcinoembryonic Antigen-Transgenic Mice: A Model for Tumor Immunotherapy
  Tumor Biology, 1995
• Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses
  AIDS Research and Human Retroviruses, 1994
• Immunotherapeutic Strategies for Cancer Using Poxvirus Vectors
  Annals of the New York Academy of Sciences, 1993
• Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine
  JNCI Journal of the National Cancer Institute, 1992
• A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)
  International Journal of Cancer, 1991
• Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus
  Vaccine, 1991